Given its role in activating the RAS pathway, there has been interest in utilizing blockade of MEK and other members of the MAP-Kinase pathway in these cancers, a paradigm that may merit further study in urachal adenocarcinoma. This evidence concerns the gene MAP2K7 and bladder urachal adenocarcinoma.